1059784--10/15/2007--GENEREX_BIOTECHNOLOGY

related topics

{stock, price, share}

{product, liability, claim}

{product, candidate, development}

{control, financial, internal}

{property, intellectual, protect}

{condition, economic, financial}

{cost, contract, operation}

{provision, law, control}

{financial, litigation, operation}

{acquisition, growth, future}

Risks Related to Our Financial Condition We have a history of losses and will incur additional losses. Risks Related to Our Financial Condition We have a history of losses and will incur additional losses. We will need additional capital. Any new equity financing will dilute current stockholders. Our research and development and marketing efforts may be highly dependent on corporate collaborators and other third parties who may not devote sufficient time, resources and attention to our programs, which may limit our efforts to successfully develop and market potential products. Risks Related to Our Technologies With the exception of Generex Oral-lyn , Glucose RapidSpray , BaBOOM! Energy Spray and GlucoBreak , our technologies and products are at an early stage of development and we cannot expect revenues in respect thereof in the foreseeable future. Until we receive regulatory approval to sell our pharmaceutical products in additional countries, our ability to generate revenues from operations may be limited and those revenues may be insufficient to sustain operations. Many factors impact our ability to obtain approvals for commercially viable products. Due to legal and factual uncertainties regarding the scope and protection afforded by patents and other proprietary rights, we may not have meaningful protection from competition. Risks Related to Marketing of Our Potential Products We may not become, or stay, profitable even if our pharmaceutical products are approved for sale. We may not be able to compete with treatments now being marketed and developed, or which may be developed and marketed in the future by other companies. If government programs and insurance companies do not agree to pay for or reimburse patients for our pharmaceutical products, our success will be impacted. Risks Related to Potential Liabilities We face significant product liability risks, which may have a negative effect on our financial condition. Risks Related to the Market for Our Common Stock Our common stock could be delisted from The NASDAQ Capital Market. If we fail to maintain compliance with applicable NASDAQ Rules and our stock is delisted from the NASDAQ Capital Market, it may become subject to Penny Stock Regulations and there will be less interest for our stock in the market. This may result in lower prices for our stock and make it more difficult for us to obtain financing. The price of our common stock may be volatile. Provisions of our Restated Certificate of Incorporation could delay or prevent the acquisition or sale of our business.

Full 10-K form ▸

1059784--10/15/2007--GENEREX_BIOTECHNOLOGY_CORP